SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending strongly as the community anticipates robust annual results, driven by surging defense contracts and civil aerospace recovery, alongside expectations for a significant share buyback program and strategic advancements in Small Modular Reactors.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amid resurfacing acquisition rumors, with French publication La Lettre reporting a potential $176-per-share offer from AstraZeneca following earlier Eli Lilly bid speculation. The community is actively discussing the differentiated profile of obefazimod for inflammatory bowel disease and the high buyout premium the company could command.

Vishay Precision Group, Inc. engages in the provision of precision measurement and sensing technologies. The firm serves a diverse array of industries and markets, including industrial, test and measurement, transportation, steel, medical, agriculture, avionics, military and space, and consumer. It operates through the following segments: Sensors, Weighing Solutions, Measurement Systems, and Corporate and Other. The Sensors segment is composed of the foil resistor and strain gage operating divisions. The Weighing Solutions segment consists of specialized modules and systems used to precisely measure weight, force torque, and pressure. The Measurement Systems segment includes specialized systems for steel production, materials development, and safety testing. The company was founded on August 28, 2009 and is headquartered in Malvern, PA.

Vishay Precision Group Inc

Vishay Precision Group (VPG) is trending following its Q4 earnings, which showcased exceptional growth in its humanoid and strategic initiatives segment, amplifying community speculation about its critical role as a precision sensor supplier for advanced humanoid robots like Tesla's Optimus and Figure AI.

Hamilton Insurance Group Ltd. is a holding company, which provides insurance and reinsurance services. It operates through the International and Bermuda segments. The International segment comprises of property, specialty, and casualty insurance and reinsurance classes of business originating from the company's London, Dublin, and Hamilton Select operations. The Bermuda segment offers property, specialty, and casualty insurance and reinsurance classes of business originating from Hamilton Re, Bermuda and Hamilton Re US and subsidiaries. The company was founded in 2013 and is headquartered in Hamilton, Bermuda.

Hamilton Insurance Group Ltd. - Ordinary Shares - Class B

Hamilton Insurance Group is gaining attention for its strong financial performance, which includes consistent earnings beats and a recent AM Best rating upgrade, leading many investors to view it as a significantly undervalued insurance play despite ongoing community discussions regarding its leadership's market communication.

Cogent Communications Holdings, Inc. engages in the provision of Internet access and Internet Protocol (IP) communications solutions. It offers Internet access and data transport through its fiber optic, IP data-only network, ethernet transport, and colocation services. The company was founded by David Schaeffer in August 1999 and is headquartered in Washington, DC.

Cogent Communications Holdings Inc

Cogent Communications is trending after a substantial dividend cut and widespread community frustration regarding management's communication on its highly leveraged balance sheet, exacerbated by recent CEO share sales; however, some investors are eyeing a potential turnaround driven by growth in AI wavelength revenue and anticipated data center asset divestitures.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

BITI is trending as community discussions intensely link Bitcoin to the "Epstein files," with many alleging the cryptocurrency was bankrolled for illicit activities and expressing strong conviction that the "pedo-currency" is a scam destined for zero. This widespread negative sentiment is driving significant interest in BITI as an inverse investment against Bitcoin's perceived impending collapse.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is gaining traction with its new listing on MEXC Meme+, energizing its dedicated "Grok's AI dog" community who are actively discussing its strong fundamentals and unique origin story as a leading AI meme coin.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following FDA approval for BYSANTI (milsaperidone) for schizophrenia and bipolar I disorder, a New Chemical Entity with patent protection until 2044. The community is actively discussing the significant undervaluation, potential for a short squeeze, and strong buyout interest from major pharmaceutical companies seeking to offset patent cliffs and capitalize on Vanda's deep pipeline, including its "mega blockbuster" Tradipitant for GLP-1 induced nausea.

Moo Deng

MOODENG Crypto is experiencing a renewed pump, with the community aggressively pushing for significant price appreciation, eyeing ambitious targets from .10 to $1. Despite being labeled a "shitcoin" by some, active discussions highlight strong buying pressure, "higher lows," and expectations for explosive runs characteristic of meme coins.

Berachain

Berachain is drawing attention for its unique Proof-of-Liquidity (PoL) consensus and impressive Total Value Locked (TVL) growth, alongside recent ecosystem upgrades and news of Grayscale's investment consideration. Community sentiment is sharply divided between conviction in its long-term potential and concerns over alleged token unlocks and market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jupiter Asset Management Ltd. Sells 116,575 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Jupiter Asset Management Ltd. decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 22.5% during the third quarter, according to the company in its most recent...

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ trimmed its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 39.3% during the third quarter, according to its most recent filing...

Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Aberdeen Group plc lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 8.2% during the third quarter, according to the company in its most recent filing with...

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Public Sector Pension Investment Board boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 10.8% during the third quarter, according to the company in its...

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +1.47% and +3.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Allianz Asset Management GmbH cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 23.1% in the 3rd quarter, according to its most recent disclosure with the...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CPRX
Catalyst Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CPRX News

CPRXCatalyst Pharmaceuticals Inc